一种化学定义的TLR3激动剂,具有抗癌活性
Julie Le Naour1,2, Sylvain Thierry3, Sarah Adriana Scuderi1,2,4
1Centre de Recherche des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Paris, France.
Oncoimmunology
|June 30, 2023
概括
一种新的托尔类受体3 (TLR3) 激动剂TL-532在临床前模型中显示出生物可用性和可接受的安全性. 这种双链RNA化合物刺激免疫反应,减少膀癌的生长,提高化疗的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 托尔类受体3 (TLR3) 激动剂,如多诺辛酸:多西酸 (poly: I: C)) 在癌症免疫治疗中表现有前途.
- 在临床试验中,Poly (I:C) 作为辅助剂用于增强瘤免疫性并克服对PD-L1阻塞的抗性.
研究的目的:
- 描述新型TLR3激动剂TL-532的药理动力学,药理动力学,机理学和毒理学特征.
- 在临床前模型中评估TL-532的抗癌疗效.
主要方法:
- 在临床前的模型中,TL-532是一种由聚I:C和聚乙烯-聚氨基酸 (聚A:U) 块组成的化学合成的双链RNA,通过肠道给药.
- 进行了药理动力学,药理动力学,机理学和毒理学评估.
- 在膀癌和纤维瘤模型中评估了抗癌疗效,包括免疫缺陷小鼠.
主要成果:
- TL-532表现出生物可用性和可接受的毒理学特征.
- TL-532刺激了化学因子和介质蛋白的产生,作为药理动力学标记物.
- 高剂量的TL-532单疗法在小鼠中减少了膀癌的生长.
- 在缺乏甲基受体-1 (FPR1) 的免疫缺陷小鼠中,TL-532恢复了在正位体纤维瘤中免疫性化疗反应.
结论:
- TL-532是一种有前途的新型TLR3激动剂,具有作为抗癌免疫治疗剂的潜力.
- 基于TL-532的临床前形状和已证明的疗效,进一步开发是有必要的.
相关概念视频
01:27Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K